Skip to main content
. Author manuscript; available in PMC: 2017 Mar 1.
Published in final edited form as: J Allergy Clin Immunol. 2015 Oct 21;137(3):889–898.e6. doi: 10.1016/j.jaci.2015.08.040

FIG 6.

FIG 6

Inhibition of PI3K, AKT or BTK mimics TLR9 induced B-cell activation defects observed in CD19-deficient B cells. Surface expression of TACI, CD23, CD86 and CD69 on purified CD19+CD27− naive B cells of healthy individuals after in vitro stimulation with F(ab′)2 anti-IgM or TLR9 ligand CpG for two days with or without addition of a PI3K-inhibitor (CAL-101), a BTK-inhibitor (PCI32765) or an AKT inhibitor (AKT-IV inhibitor) was analyzed by flow cytometry. Dot blots of a representative experiments are shown in A and the data of five independent experiments is summarized in B. Each bar represents the mean ± SEM frequency, horizontal dashed lines represent the mean of the unstimulated samples. (* p<0.05; ** p<0.01; *** p<0.001).